Nike names Pfizer's Denton as CFO, Q4 seen in line with guidance

Nike appointed Pfizer's David Denton as CFO and said fourth-quarter results will be in line with guidance, as the sportswear giant navigates a prolonged turnaround.

"David brings deep financial leadership experience across global consumer and healthcare businesses," Nike Chief Executive Officer Elliott Hill said in a statement.

Denton joins as executive vice president and CFO, succeeding Matthew Friend, who is stepping down. The transition comes nearly two years into Hill's tenure, during which Nike has struggled to revive growth as U.S. lifestyle demand weakens and product innovation lags.

The CFO change introduces uncertainty about Nike's financial strategy. Shares fell 1.4% in premarket trading Tuesday after Evercore ISI downgraded the stock to In-Line from Outperform, cutting its price target to $46 from $57.

Evercore analyst Michael Binetti cited persistent wholesale channel resets, deteriorating U.S. sales and supply chain disruptions in Europe that delayed World Cup merchandise. The brokerage lowered its fiscal 2027 EPS estimate to $1.65 from $1.70, below the $1.82 consensus.

Nike's flexible retailer returns policy is backfiring, with some retailers maximizing cancellations and leaving the company with higher-than-expected inventory, Binetti said.

Some bright spots remain. Performance categories such as Nike Run continue to deliver solid results, and a potential $1 billion tariff refund could provide additional resources for marketing. Consensus expectations for the fourth quarter appear achievable, Evercore said.

Nike trades at about 1.5 times enterprise value to sales, near its lowest level in roughly 15 years, limiting further downside, according to the brokerage.

The CFO appointment signals a strategic reset as Nike prepares for a key investor day in fall 2026. Investors will watch the Q4 earnings release for details on the turnaround timeline and whether the company can stabilize revenue after two years of declining sales.

This article is for informational purposes only and does not constitute investment advice.